Argenica Therapeutics Ltd

AGN

Company Profile

  • Business description

    Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

  • Contact

    117 Broadway
    Unit 4
    NedlandsWA6009
    AUS

    T: +61 893293396

    https://www.argenica.com.au

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

Stocks News & Analysis

stocks

Undervalued ASX income play

Major development projects remain on schedule.
stocks

Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?

With the monetization of GenAI, here’s what we think of Alphabet’s stock
stocks

Going into earnings, Is Meta stock a buy, a sell, or fairly valued?

With a focus on leveraging its AI investments, here’s what we think of Meta stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,929.203.000.03%
CAC 407,798.2224.45-0.31%
DAX 4024,307.8018.290.08%
Dow JONES (US)44,323.0719.12-0.04%
FTSE 1009,012.9920.870.23%
HKSE25,031.0236.880.15%
NASDAQ20,974.1878.520.38%
Nikkei 22539,682.72136.39-0.34%
NZX 50 Index12,810.14151.37-1.17%
S&P 5006,305.608.810.14%
S&P/ASX 2008,667.001.20-0.01%
SSE Composite Index3,568.788.990.25%

Market Movers